SCHEMBL4897487

SCHEMBL4897487

CCN(c1nc2cc(-c3ccccc3)ccc2o1)S(=O)(=O)c1ccc(C)c(C(=O)OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
C1R P00736 2/20 0.42
PRSS1 P07477 2/20 0.42
CETP P11597 2/20 0.42
GAA P10253 2/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
PTPN22 Q9Y2R2 7/20 0.41
PTPN1 P18031 4/20 0.40
PTPN12 Q05209 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN5 P54829 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904431 0.91 C1R (0.45) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4906070 0.90 RAB9A (0.46) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4906365 0.89 ALDH1A1 (0.42) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4902746 0.87 ALDH1A1 (0.45) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4895332 0.86 MEN1 (0.39) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4905178 0.84 PTPN1 (0.47) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4895610 0.82 ALDH1A1 (0.41) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4899819 0.81 C1R (0.51) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4899763 0.81 ALDH1A1 (0.41) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4903840 0.80 HPGD (0.47) MEN1NPC1RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD MEN1 4855/4885NPC1 59/4885RAB9A 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.